Fifty-one patients with relapsed or resistant multiple myeloma received clarithromycin p.o. at the dose of 500 mg b.i.d Thirteen patients did not complete the planned therapeutic program of 12 weeks due to side effects or progression. Among the 38 evaluable patients, objective or minor responses occurred in one and two patients, respectively. Our data do not support the use of clarithromycin for the treatment of advanced multiple myeloma.
|Number of pages||2|
|Publication status||Published - 2002|
ASJC Scopus subject areas